ARMATA PHARMACEUTICALS, INC. Temporary Equity, Accretion of Dividends
ARMATA PHARMACEUTICALS, INC. (ARMP) reported Temporary Equity, Accretion of Dividends of -$365.00 thousand for the 12-month period ending 2016-12-31, per its 10-K filed 2018-03-14.
Discontinued › Shareholders' Equity
us-gaap:TemporaryEquityAccretionOfDividends · last filed 2018-03-14
- ARMATA PHARMACEUTICALS, INC. temporary equity, accretion of dividends for the quarter ending 2016-12-31 was $0.00.
- ARMATA PHARMACEUTICALS, INC. temporary equity, accretion of dividends for the quarter ending 2016-09-30 was $0.00.
- ARMATA PHARMACEUTICALS, INC. temporary equity, accretion of dividends for the quarter ending 2016-06-30 was -$42.00K.
- ARMATA PHARMACEUTICALS, INC. temporary equity, accretion of dividends for the quarter ending 2016-03-31 was -$323.00K.
- ARMATA PHARMACEUTICALS, INC. temporary equity, accretion of dividends for fiscal 2016 was -$365.00K.
- ARMATA PHARMACEUTICALS, INC. temporary equity, accretion of dividends for fiscal 2015 was -$1.31M.
- ARMATA PHARMACEUTICALS, INC. temporary equity, accretion of dividends for fiscal 2014 was -$1.28M.
| Period end | Temporary Equity, Accretion of Dividends 3 month | Temporary Equity, Accretion of Dividends 6 month | Temporary Equity, Accretion of Dividends 9 month | Temporary Equity, Accretion of Dividends 12 month | Temporary Equity, Accretion of Dividends 12 month as first filed |
|---|---|---|---|---|---|
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-14 | $0.00 derived: sum of 2 quarters · filed 2018-03-14 | -$42.00K derived: sum of 3 quarters · filed 2018-03-14 | -$365.00K 10-K · filed 2018-03-14 | |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | -$42.00K derived: sum of 2 quarters · filed 2016-11-10 | -$365.00K 10-Q · filed 2016-11-10 | -$680.00K derived: sum of 4 quarters · filed 2017-03-27 | |
| 2016-06-30 | -$42.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-15 | -$365.00K 10-Q · filed 2016-08-15 | -$680.00K derived: sum of 3 quarters · filed 2017-03-27 | -$2.35M derived: sum of 4 quarters · filed 2017-03-27 | |
| 2016-03-31 | -$323.00K 10-Q · filed 2016-05-12 | -$638.00K derived: sum of 2 quarters · filed 2017-03-27 | -$2.30M derived: sum of 3 quarters · filed 2017-03-27 | ||
| 2015-12-31 | -$315.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-27 | -$1.98M derived: sum of 2 quarters · filed 2017-03-27 | -$1.31M 10-K · filed 2017-03-27 | ||
| 2015-09-30 | -$1.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-16 | -$992.00K 10-Q · filed 2015-11-16 | |||
| 2015-06-30 | $674.00K 10-Q · filed 2015-08-13 | ||||
| 2014-12-31 | -$1.28M 10-K · filed 2016-03-30 | $1.28M 10-Q · filed 2015-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |